Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 220

Posts Tagged ‘Oncology’

Nuovo Vice President della Business Unit Oncology di AstraZeneca Italia

Posted by fidest press agency su sabato, 18 aprile 2020

Mirko Merletti è il nuovo Vice President Business Unit Oncology di AstraZeneca Italia, filiale locale dell’azienda biofarmaceutica globale che proprio in oncologia vede una pipeline in rapida crescita che permetterà il passaggio da 3 a 5 franchise nel 2020.Dopo la laurea in economia all’Università Bocconi di Milano e il Master in Business Administration presso la SDA Bocconi, Mirko Merletti ha maturato solide esperienze professionali in ambito biofarmaceutico e in particolare nell’area onco-ematologica.Entrato in Novartis nel 2007, ha sviluppato esperienze manageriali in Europa, contribuendo alla definizione della strategia di lancio di nuove molecole in oncologia ed ematologia e ponendo le basi per la crescita dell’azienda in questo ambito.
Nel 2015 è stato nominato Head of Market Access Novartis Oncology Italy e, nel 2017, Business Franchise per l’onco-ematologia sempre in Italia. Inoltre, ha contribuito al rafforzamento della presenza di Novartis nell’ambito delle neuroscienze, ricoprendo dal 2019 la carica di Commercial Director Neuroscience Europe e preparando il lancio di tre nuove molecole.
Nel corso degli anni, Mirko Merletti ha acquisito diverse competenze trasversali: una grande esperienza nel finance ma anche nel lancio di nuovi prodotti, nello sviluppo delle strategie di commercializzazione, accesso al mercato e rapporti istituzionali.
“Nel settore oncologico, AstraZeneca offre un portafoglio in rapida crescita di nuovi farmaci potenzialmente in grado di migliorare la vita dei pazienti e il futuro dell’Azienda – spiega il dott. Merletti -. Sono dunque onorato di assumere questo ruolo, di mettere a disposizione la mia esperienza e affrontare con tutto il mio team le sfide che verranno e che sono certo ci daranno la possibilità di offrire ai clinici, e di conseguenza ai pazienti, delle soluzioni terapeutiche ancora più mirate ed efficaci. Per farlo sfrutteremo la potenza di quattro piattaforme scientifiche (Immuno-Oncologia, driver tumorali e resistenza, risposta al danno del DNA e coniugati farmaco-anticorpi) e sosterremo lo sviluppo delle combinazioni personalizzate”.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

AgilVax to Present at the 2019 NYC Oncology Investor Conference

Posted by fidest press agency su domenica, 10 novembre 2019

Conference on November 12, 2019 at 5:30 PM (ET). The conference is being held at the Perkins Coie law firm, 1155 6th Ave, New York City, NY.AgilVax Inc., announced today that Joseph Patti, PhD, President and Chief Executive Officer, will present an overview of the Company and provide an update on its portfolio of targeted antibody-based therapies addressing multiple cancers at the NYC Oncology Investor.
AgilVax has demonstrated in preclinical in vivo models that antibodies to xCT were able to reduce primary tumor formation and the number of lung metastases. xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVax has multiple solutions to target cancer cells that overexpress xCT and when used in combination with existing therapies or alone have the potential to create a durable response in patients suffering from colorectal and other metastatic cancers.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

34th Annual Meeting of the Society for Immunotherapy of Cancer

Posted by fidest press agency su sabato, 9 novembre 2019

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, will present clinical and pharmacodynamic biomarker data from the solid tumor combination cohorts of the ongoing ALX148 Phase 1 clinical program at the SITC 34th Annual Meeting. As of September 23, 2019, eighty-two patients with advanced malignancies were administered ALX148 in combination with standard regimens of either trastuzumab (n=30) or pembrolizumab (n=52). Objective responses were observed in expansion cohorts for response-evaluable patients with gastric/gastroesophageal junction cancer (G/GEJ) and squamous cell carcinoma of the head and neck (HNSCC). A summary of results is described below.Patients with HER2 positive G/GEJ (n=19) whose tumors had progressed on prior systemic therapy, including HER2-targeted therapy, demonstrated an objective response rate (ORR) of 21% and a disease control rate (DCR) of 26%.Patients with HNSCC (n=20) whose tumors had progressed on prior platinum therapy, demonstrated an ORR of 20% and a DCR of 30%. In checkpoint inhibitor-naïve subjects (n=10), an ORR of 40% and a DCR of 40% were observed.ALX148 was well tolerated with no maximum tolerated dose reached. Treatment-related adverse events were mostly of low grade and frequency.Complete CD47 target occupancy was observed throughout the dosing interval with no impact on circulating immune cell populations following ALX148 combination treatments.Immunohistochemistry analysis using paired pre- and on-study tumor biopsies showed a statistically significant increase in intratumoral macrophages in pembrolizumab and trastuzumab combinations, and an increase in intratumoral CD8+ cells in combination with pembrolizumab.RNA expression analysis from paired tumor biopsies suggest increased dendritic cells, cytotoxic cells, as well as gene signatures associated with antigen presentation, myeloid cell activity and tumor inflammation following ALX148 in combination with pembrolizumab.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

Posted by fidest press agency su giovedì, 7 novembre 2019

AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the Company’s proposal to proceed with a New Drug Application (NDA) for tivozanib.The Company previously announced that the TIVO-3 trial met its primary endpoint of demonstrating a significant improvement in PFS. The study also demonstrated a significant improvement in the secondary endpoint of overall response rate. The August 2019 analysis of the secondary endpoint of OS was the second prespecified interim OS analysis of the TIVO-3 trial, and showed an updated OS hazard ratio (HR) of 0.99 at two years from the last patient enrolled in the study.In the FDA’s preliminary feedback, based on its assessment of the totality of evidence presented to date, the FDA recommended that the Company not submit an NDA at this time. The FDA stated that it remained concerned about the results of TIVO-3 in the context of the overall development of tivozanib. The FDA noted that the Company’s current interim OS results do not abrogate the FDA’s concerns over detriment and that those results may worsen with final analysis at 263 events, and that the median OS for tivozanib is worse than that of sorafenib.In view of the changing first-line treatment landscape as well as the FDA’s continued concerns, the Company informed the FDA that it intends to narrow its proposed indication to relapsed/refractory RCC. At the meeting, the FDA acknowledged AVEO’s responses and reiterated its concerns about the survival information and the totality of data. The FDA noted that the choice to submit the data is the Company’s, and that a discussion with the Oncologic Drug Advisory Committee will likely be required. The FDA said that if AVEO wishes to proceed with a revised OS analysis in June 2020, AVEO should submit an updated statistical analysis plan (SAP) with a planned OS update based on the projected number of events at that time.AVEO intends to submit to the FDA an update to the SAP for the final OS analysis consistent with these discussions, followed by an NDA submission in the first quarter of 2020. AVEO expects to report the final OS analysis in June 2020 based on a May 1, 2020 cutoff, at which point the Company estimates that the study will have reached approximately 263 OS events, as discussed with the FDA. The FDA and the Company agreed that if the final analysis yields an OS HR above 1.00, the Company will withdraw its NDA application.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

2019 Onmark Oncology Practice Summit

Posted by fidest press agency su venerdì, 25 ottobre 2019

Austin (Tx) The Summit is an annual program offered by McKesson to help practices develop strategies and tactics that enable them to run more efficiently in the challenging value-based landscape. Through a series of lectures, panel discussions and interactive exercises, practices gained experience developing and implementing plans to strengthen their critical operations, helping to ensure practice success while keeping patient care the number one priority. This year’s Summit agenda featured a wealth of topics surrounding emerging healthcare trends, examples of successful practice transformations, and resources to help community-based oncology practices succeed in an increasingly competitive, ever-changing environment. Key activities during the Summit included: Presentations from experts who shared their point of view on new regulations and major trends affecting oncology Breakout sessions focused on strategic planning, employee engagement and leading through change
Opportunities to collaborate and network with peers as well as McKesson’s leadership team and subject matter experts
Clinical workshops about groundbreaking treatments and methods to enhance patient care. Oncologists and key practice staff participated in expert-led sessions on various topics with a unifying focus on leading through change. One panel included discussions on successful implementation of biosimilars—addressing the clinical, economic and operational impacts to consider as new therapies enter the market. Another panel brought together experts to help practices navigate the evolving community oncology landscape to preserve and enhance the ability to serve patients. Additionally, McKesson introduced biomarker test guidelines to support precision medicine as well as its new strategic planning services designed to help practices succeed and grow into the future.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Strategic Planning Solution for Community-Based Oncology Customers

Posted by fidest press agency su lunedì, 7 ottobre 2019

A new strategic planning solution for oncology practices is now available to customers through McKesson’s Business Advisory Services, a team of experts dedicated to helping specialty practices solve financial and operational challenges through consulting, analytics and technology. Strategic planning is a comprehensive engagement solution designed to help practices define priorities, identify strategies and tactics to meet their selected goals, and allocate resources to achieve their vision. The new offering was introduced today during the Onmark Oncology Practice Summit.
McKesson’s strategic planning process helps practices create a vision for the future, while equipping them with short-term tactical planning to drive momentum and results. The comprehensive planning process starts with an analysis of the practice’s data, so the McKesson team thoroughly understands its challenges and opportunities and the practice has baseline metrics to guide its discussion and decisions. This is followed by a facilitated retreat with physicians and key staff to align on top priorities and culminates in a detailed three-year action plan for each initiative selected by the practice, providing the structure to make daily decisions that follow the larger vision.Practices receive a wealth of benefits from strategic planning. Most importantly, the process helps create a common culture within a practice, fostering collegiality and teamwork by unifying physicians and staff around shared priorities and goals. Discussions are efficiently managed by McKesson’s experienced planning team to help participants resolve differences and come to a consensus. Through tried and true analytics designed to enable strategic planning conversations, practices can harness their own financial, patient and geographic data in a new and valuable way, allowing leadership to make sound data-driven decisions about their strategic priorities. The planning team also provides an objective, fresh perspective of the practice’s situation, offering national benchmarks for unbiased comparison.While many of the techniques of effective strategic planning can be employed across various industries, successful planning for community oncology practices requires specific expertise, including an understanding of how community oncology practices operate and a deep knowledge of national trends. McKesson’s Business Advisory Services is staffed with oncology experts with real-world knowledge and unparalleled expertise gained through managing more than 50 practices in The US Oncology Network. With more than 25 years of experience in helping oncology practices thrive in challenging environments and markets, McKesson is dedicated to empowering practices to succeed in today’s dynamic value-based landscape.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

European Society for Medical Oncology 2019 Congress

Posted by fidest press agency su venerdì, 27 settembre 2019

Basel, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that results from a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, taking place from 27 September – 1 October in Barcelona, Spain. A total of 100 abstracts and 15 late-breaking abstracts that include a Roche medicine will be presented at this year’s congress.”We are excited to present a number of key datasets across a broad range of diseases at ESMO this year, including results from our Tecentriq combination study in people with previously untreated advanced bladder cancer, the first positive Phase III cancer immunotherapy trial in this setting. In addition, we will present data from our Phase III Tecentriq monotherapy study in previously untreated advanced lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “We will also share data from a study using Foundation Medicine’s liquid (blood) biopsy, a more patient-friendly approach to diagnosing and treating cancer. The results of the first cohort of this study involving ALK+ non-small cell lung cancer patients who received Alecensa will be presented at the congress.”

Posted in Estero/world news, Lettere al direttore/Letters to the publisher | Contrassegnato da tag: , | Leave a Comment »

Oncology therapies

Posted by fidest press agency su lunedì, 9 settembre 2019

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond. New clinical data from the poziotinib Phase 2 investigator-initiated trial in NSCLC EGFR exon 20 mutations, conducted by the University of Texas MD Anderson Cancer Center will be presented during the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place in Barcelona, Spain from September 7-10, 2019. “There continues to be investigator interest in poziotinib’s unique characteristics to address NSCLC mutations, including exon 20 and other mutations, which have limited or no treatment options,” said Francois Lebel, M.D., F.R.C.P.C., Chief Medical Officer of Spectrum Pharmaceuticals. “The data presented at this conference by our scientific collaborators at MD Anderson further expands the body of evidence supporting poziotinib’s role in lung cancer and helps us gain new insights into its full potential.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

“2nd Annual Next Gen Immuno-Oncology Congress”

Posted by fidest press agency su sabato, 31 agosto 2019

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies, and Cell Therapies.Clinical trials have shown that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy.
Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal, and Bispecific Antibodies and more.
A platform to meet experts from Pharma, biopharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

MJH Associates Announces Partnership with Hematology-Oncology Associates of Central New York

Posted by fidest press agency su mercoledì, 31 luglio 2019

MJH Associates‚ Inc., a full-service multimedia medical media company, announces a Strategic Alliance Partnership (SAP) between Hematology-Oncology Associates of Central New York (HOA) and three of its premiere brands, Targeted Oncology™, The American Journal of Managed Care® (AJMC®) and Pharmacy Times®.
HOA is a multispecialty, multilocation, highly integrated and comprehensive oncology practice that is also a member of the Community Oncology Alliance. In addition to its robust clinical practice, HOA leads local advocacy for access, care integration and value based-care. HOA is the only oncology practice in Central New York certified for quality by the American Society of Clinical Oncology (ASCO)’s Quality Oncology Practice Initiative. HOA participates as one of the National Cancer Institute’s clinical research partners and runs several patient-focused programs in survivorship and patient education outreach for cancer and metastatic disease.HOA offers CyberKnife; high-tech radiation therapy; diagnostic imaging services; lab, infusion and dispensing pharmacy services; nutritional consultations; cancer rehabilitation/physical therapy; and palliative care, survivorship and social work services to thousands of patients. HOA has certifications with the American College of Radiology and ASCO, and it has a dispensing pharmacy certified by the Accreditation Commission for Health Care as a Specialty Pharmacy with a Distinction in Oncology.The MJH SAP program is constantly building a community of health plans, advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information for the ultimate benefit of patients and their families and improving patient care. As part of this joint effort, Targeted Oncology™, AJMC® and Pharmacy Times® will work with HOA to share exclusive digital content and bring clinical educational opportunities to its community through case-based regional programming.

Posted in Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

Posted by fidest press agency su giovedì, 11 luglio 2019

Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced the expansion of its long-term strategic alliance with Celgene Corporation to include Nimbus’ HPK1 inhibitor program.
Under the terms of the agreement, Celgene will receive an option to acquire the program up through a clinical inflection point. Nimbus will retain full control of research and development activities for the program prior to the program’s option point. Financial terms will remain undisclosed until Celgene exercises its option to acquire the program.
Hematopoietic Progenitor Kinase 1 (HPK1), a member of the MAP4K family, is an intracellular negative regulator of T cell proliferation and signaling and plays a key role in dendritic cell activation. The challenge with HPK1 thus far has been the ability of small molecules to achieve potency and selectivity profiles that do not inhibit other T cell kinases or MAP4K family members. Given its role in both T cells and dendritic cells, and an opportunity for working synergistically in upregulating immune system surveillance of cancer, HPK1 has been a highly prized target in immuno-oncology. Nimbus will continue to own and develop its potent small molecule HPK1 inhibitors that are highly selective against relevant off targets and possess robust cellular activity.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

Posted by fidest press agency su sabato, 18 maggio 2019

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.The accepted abstracts summarize clinical trials in which Rubraca is being evaluated as a single agent and as combination therapy with nivolumab in a variety of solid tumor types including ovarian, prostate, biliary tract and endometrial cancers. These include additional genomic profiling data from TRITON2, and new data from extended follow up of patients in ARIEL3.“Increased understanding about the role of genomic mutations, as well as the growing number and type of oncology therapies, offer tremendous potential for us to more precisely target and improve treatment of the most challenging cancers,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “In our own clinical development program and in investigator-led studies, we are evaluating the utility of Rubraca in multiple solid tumor types where there is genomic rationale, including among patients with BRCA1/2 mutations as well as mutations in other genes that play a role in DNA repair.”
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe. Please visit http://www.clovisoncology.com for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

American Oncology Network, LLC Appoints Inaugural Advisory Group

Posted by fidest press agency su lunedì, 8 aprile 2019

American Oncology Network, LLC Appoints Inaugural Advisory GroupWith a mission to support long-term viability of community oncology, the American Oncology Network, LLC (AON) has created a new advisory group to provide high-level strategic guidance to its practices and physicians.Consisting of AON physicians, executive management and administrative specialists, the group will advise on a range of trends impacting clinical and practice activities. The group’s goal is to serve as an advocate for AON’s physicians and physician groups, providing counsel and support on all issues related to business improvement, strategic development, quality and compliance.“It is a pleasure for us to introduce the AON Advisory Group to our practices, who will benefit from its recommendations,” said AON CEO Brad Prechtl. “The group will provide another layer of support to enhance practice services.”Inaugural group members include physicians from across the nation, such as Dr. Patrick Elwood and Dr. Taral Patel from the Zangmeister Cancer Center in Ohio; Dr. Michael Castine III from the Hematology/Oncology Clinic in Louisiana; Dr. Stephen “Fred” Divers from the Genesis Cancer Center in Arkansas; and Dr. Rangappa Rajendra from Oncology/Hematology of Loudoun and Reston in Virginia.
The AON Advisory Group’s executive management team members include AON CEO Brad Prechtl, COO Todd Schonherz, Regional Senior Vice President Steven Swart, Chief Revenue Cycle Officer Sarah Cevallos, Chief Information Officer Mark Moch, AON Board member and Strategic Advisor Dr. William Harwin, and AON Board Member Dr. Stephen Orman.AON is an alliance of physicians and seasoned health care leaders partnering to ensure the long-term success of community oncology. With more than three decades of expertise in all areas of oncology practice management, AON enables physicians to focus on what matters most — providing the highest-quality care for patients.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

American Oncology Network, LLC (AON) Introduces Specialty Oral Oncolytic Pharmacy

Posted by fidest press agency su martedì, 26 marzo 2019

The American Oncology Network, LLC (AON), an alliance of physicians and seasoned healthcare leaders, provides a unique array of support services to its affiliated community-based oncology practices, including in-house specialty pharmacy services. The AON Pharmacy streamlines the process of filling prescriptions for cancer patients who are being treated with oral oncolytic medications. According to the Community Oncology Alliance (COA), approximately 25% to 35% of all cancer drugs are currently available in pill form and that percentage is increasing each year.AON CEO Brad Prechtl, MBA, said, “Through the American Oncology Network, community oncology practices across the nation now have access to practice-proven solutions that bring tremendous value and benefit to their patients. The AON Pharmacy is a prime example of this. Pharmacy staff members not only handle the complicated insurance authorization process, they also work with patients and educate them about potential side effects of these powerful cancer drugs and ensure that patients are compliant and understand how to take prescribed medications.”Director of Pharmacy Ray Bailey added, “Our pharmacists are experts in oncology medications and they are available to speak with both patients and physicians, as needed. Through our electronic medical record (EMR), AON pharmacists can view a patient’s chart and then work directly with the patient’s oncologist to best manage any side effects of the oral therapies.”AON Board Member Dr. William Harwin pointed out, “When someone is diagnosed with cancer, he or she doesn’t want to wait several weeks to receive prescribed medications; yet, many of the smaller community oncology practices in the AON network don’t have the infrastructure to provide speedy access to oral oncology drugs. Through the AON Pharmacy, which ships directly to patients’ homes, usually within 48 to 72 hours, patients have easier, more convenient and much faster access to the medications they need.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences

Posted by fidest press agency su domenica, 3 marzo 2019

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that preclinical data for its SIRPα antibody research program will be presented at the 2019 Keystone Symposia Conference (Keystone), Cancer Immunotherapy in Whistler, British Columbia and the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.CD47/SIRPα interaction is a key checkpoint mechanism exploited by cancer cells to escape immunological surveillance. While CD47 is widely expressed in human cells, SIRPα, the CD47 inhibitory receptor, is mainly expressed in myeloid cells and neurons. ALX148, a CD47 blocker with an inactive Fc domain, is generally well tolerated and demonstrates anti-cancer activity in combination with trastuzumab and pembrolizumab in patients with anti-HER2 and checkpoint inhibitor resistant/refractory disease (SITC 2018, P335). Another approach to block this interaction is to target SIRPα.“Targeting the CD47/SIRPα pathway is an exciting new approach that shows promise in clinical trials. By targeting SIRPα, we can investigate the similarities and differences of an orthogonal strategy to inhibit this axis,” said Hong Wan, Ph.D., ALX Oncology’s Chief Scientific Officer. “Our panel of proprietary high affinity monoclonal antibodies provides diverse epitope coverage across the extracellular surface of SIRPα. These antibodies are cross-reactive to human, monkey and rodent SIRPα variants, which enables robust clinical translation. Importantly, these antibodies bind to all human SIRPα variants, a critical attribute for a global patient population.” ALX Oncology’s SIRPα antibodies enhance the antitumor activity of immune checkpoint inhibitors, with reduction of metastases, eradication of tumors, and acquisition of memory immune response in tumor-bearing mice with intact immune systems. The cellular immune response in syngeneic models shows that these SIRPα antibodies enhance innate and adaptive anti-cancer immunity, providing a rationale for combination with other immunotherapies. In an exploratory toxicology study in monkeys, the selected SIRPα antibodies demonstrate a favorable pharmacokinetic, target occupancy and tolerability profile.Together, these preclinical data provide a compelling rationale to advance the development of anti-SIRPα therapy for patients with cancer.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling

Posted by fidest press agency su giovedì, 1 novembre 2018

Illumina, Inc. (NASDAQ: ILMN) today announces the launch of TruSightTM Oncology 500 (TSO 500), a comprehensive pan-cancer assay designed to identify known and emerging tumor biomarkers. TruSight Oncology 500 utilizes both DNA and RNA from subject tumor samples to identify key somatic variants underlying tumor progression, such as small DNA variants, fusions, and splice variants. Importantly, TruSight Oncology 500 can measure tumor mutational burden (TMB) and microsatellite instability (MSI), features that are potentially key biomarkers for emerging immunotherapies. TruSight Oncology 500 is for research use only and will ship in Q1 2019.Molecular testing in lung cancer has been at the forefront of precision oncology. The use of targeted therapies is associated with improved outcomes in some patients, and currently requires testing multiple biomarkers, such as EGFR mutations, ALK fusions, and ROS fusions, among others. Recently, TMB gained prominence as a biomarker that demonstrates better response and survival from immune checkpoint inhibitors in patients exhibiting high TMB, necessitating the need for comprehensive sequencing. Reliable measurement of TMB in a tumor-only workflow requires sequencing of approximately 1Mb or greater, specific and sensitive variant calling, as well as bioinformatic methods to flag and remove germline variants. Given the increasing number of biomarkers required to fully understand the optimal therapeutic course, assays like TruSight Oncology 500—one of the largest and most comprehensive panels to-date—encompasses all of these biomarkers, making it an ideal choice for cancer researchers today.“The importance of tumor mutational burden as a biomarker to predict immune checkpoint inhibition response continues to grow in non-small cell lung cancer,” said Albrecht Stenzinger, MD, pathologist at University Hospital Heidelberg, Germany. “However, the detection of somatic biomarkers, such as ALK fusions and EGFR small variants, are also vital. The workflow of TSO 500, using both DNA and RNA, enables laboratories to evaluate TMB, as well as small DNA variants and fusions simultaneously, ultimately saving time and preserving precious samples.” Pharmaceutical partners and payers are shifting toward deeper, broader sequencing to help predict which patients may benefit from new treatments including immunotherapies, targeted therapies and the many potential combinations. Recently, Bristol-Myers Squibb Company (NYSE: BMY) and Illumina announced a collaboration to develop and globally commercialize companion diagnostics, based on TruSight Oncology 500 content, to support Bristol-Myers Squibb’s oncology portfolio.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AVEO Oncology to Participate in Upcoming Conferences

Posted by fidest press agency su mercoledì, 26 settembre 2018

AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company’s strategy is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. The Company is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced renal cell carcinoma (“RCC”). The Company has outlicensed tivozanib (FOTIVDA®) for oncology in Europe and other territories outside of North America. Tivozanib is approved in the European Union, as well as Norway and Iceland, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC. The Company has entered into partnerships to fund the development and commercialization of AV-203 (CAN017) and ficlatuzumab, both clinical stage assets in oncology. The Company is currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension. The Company has recently regained the rights to its AV-380 program for the potential treatment of cachexia and is considering a variety of options to advance the program’s development. http://www.aveooncology.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

Posted by fidest press agency su sabato, 2 giugno 2018

Integral Molecular, the industry leader in membrane protein antibody discovery, announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic syndrome (GLUT4 and CB1). These therapeutic assets are among the first released in a pipeline of antibodies being isolated with the MPS Discovery Engine®, which is tailored for the discovery of rare, functional antibodies against complex membrane protein targets.In a paper published in PNAS (Tucker et al., May 2018), the company revealed the discovery of the first functional MAbs against GLUT4, an insulin-responsive glucose transporter important in diabetes. Epitope mapping showed that MAbs LM043 and LM048 are rare state-specific MAbs, selectively binding only certain active forms of the GLUT4 transporter.Last month at the PEGS protein engineering conference, Integral Molecular presented their discovery of antagonist MAb IM-102 against CB1 for NASH (inflammatory liver disease). IM-102 inhibits CB1 with 23 times greater potency than a benchmark MAb currently in phase 1 clinical trials. At the AACR conference this spring, the company presented its discovery of highly specific antibodies against Claudin 6, an established membrane protein target in ovarian cancer.
Ross Chambers, VP of Antibody Discovery, attributes the company’s 95% success rate in MAb isolation to optimization of its antibody discovery platform: “Our proprietary technologies allow us to obtain hundreds of diverse, high-affinity antibodies against complex targets, enabling us to discover antibodies with rare functional properties.”Integral Molecular’s MPS Discovery Engine® encompasses a technology suite that overcomes the obstacles of working with highly homologous and structurally complex targets. This suite includes antigen engineering and presentation on Lipoparticles, immunization of divergent species, and use of B-cell cloning to recover rare antibodies. Integral Molecular is currently isolating MAbs against dozens of membrane protein targets.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

UNC Cancer Care at Rockingham, a Service of UNC Hospitals, Adds Medical Oncology, Offering Comprehensive Cancer Care

Posted by fidest press agency su sabato, 12 maggio 2018

UNC Health Care announces the opening of UNC Cancer Care at Rockingham, a service of UNC Hospitals, on May 15. The newly named and expanded clinic will offer comprehensive cancer care and support services close to home for patients and their families.The clinic, previously known as the Smith McMichael Cancer Center, will now offer Medical Oncology and infusion services, in addition to the Radiation Oncology services that began earlier this year. Medical oncologist Dr. Bennett Winston Yu will work closely with patients starting May 15. Dr. Thomas C. Shea, a professor with the UNC School of Medicine and medical co-director of the UNC Bone Marrow Transplant and Cellular Therapy Program, will support Dr. Yu. They join Dr. Mohit Kasibhatla, a UNC Radiation Oncologist who began providing care on April 1.“When this hospital joined UNC Health Care last year, one of our top goals was to expand the care and services available in our community,” said Dana Weston, president of UNC Rockingham. “Unfortunately, cancer strikes far too often in this region. We are proud to offer much-needed and comprehensive cancer care and support that’s convenient for our patients and their families.” Patients receiving care at UNC Cancer Care at Rockingham will be able to readily access the expertise of UNC Cancer Care’s providers, a site close to home for infusion therapy, and will receive high-quality, compassionate and state-of-the-art treatment for a wide range of cancers. Surgical services, offered at UNC Rockingham Hospital, is another compliment to the care available.UNC Rockingham Health Care, formerly known as Morehead Memorial Hospital, became part of UNC Health Care and unveiled its new name on Jan.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

MUSC Health and Alliance Oncology Expand Cancer Care in Beaufort, S.C.

Posted by fidest press agency su mercoledì, 7 febbraio 2018

san frnciscoSan Francisco. Alliance Oncology and the Medical University of South Carolina Health System (MUSC Health) announced today that they will partner with Beaufort Memorial Hospital to relocate and expand the hospital’s radiation oncology center to its main campus in late 2018. This project represents Alliance Oncology’s vision to be a driver in transforming healthcare by partnering with leading providers to expand regional services to communities – thus giving patients and their providers improved access, convenience and services closer to home. “In partnership with MUSC Health and Beaufort Memorial Hospital we are excited to add this location benefitting the local Beaufort community, and to augment academic cancer care services in the region,” said Greg Spurlock, President of Alliance Oncology. “As one of the nation’s leading providers of cancer care, this center will join Alliance affiliated locations across the country in providing high-quality, patient-centered services in partnership with premier cancer care providers and caregivers.” At the new Beaufort Memorial Keyserling Cancer Center, an MUSC clinical advisory committee will collaborate closely with local oncology experts and a dedicated clinical liaison will be onsite in the radiation oncology center. This expands upon the collaboration that was formed in 2016 when Beaufort Memorial Keyserling Cancer Center began enrolling qualifying cancer patients in clinical trials through an affiliation with the National Cancer Institute-designated Hollings Cancer Center at MUSC. “Given the needs of our patients throughout the state, it is imperative that we find innovative affiliations such as this one to ensure we are reaching all of those who need the expertise of our teams,” said Patrick J. Cawley, M.D., CEO, MUSC Health and Vice President for Health Affairs at Medical University of South Carolina. “We are excited and pleased to work with our colleagues at Alliance Oncology and Beaufort Memorial to bring the expertise of the Hollings Cancer Center even closer to those who need us.” “Beaufort Memorial Hospital has been providing outstanding cancer care to the community for more than a decade,” says Russell Baxley, MHA, President and CEO of Beaufort Memorial Hospital. “Our new and expanded partnership with MUSC and Alliance Oncology allows us to offer cutting-edge technology and resources locally, providing the latest in cancer care to our patients.”Alliance Oncology partners directly with hospitals and physicians to develop fully integrated oncology programs. Providing a full range of inpatient and outpatient service line capabilities, Alliance Oncology’s comprehensive approach to cancer care affords its partners the speed-to-market, quality clinical outcomes, patient satisfaction and operational expertise that sets them apart from the competition. (foto: san francisco)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »